PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Negative EBIT growth while CRVO is at 56.17%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
3.86%
Operating income growth under 50% of CRVO's 689.69%. Michael Burry would be concerned about deeper cost or sales issues.
-1.47%
Negative net income growth while CRVO stands at 52.71%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
12.77%
EPS growth under 50% of CRVO's 100.00%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
13.49%
Diluted EPS growth under 50% of CRVO's 100.00%. Michael Burry would worry about an eroding competitive position or excessive dilution.
16.41%
Slight or no buybacks while CRVO is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
17.29%
Slight or no buyback while CRVO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
No Data
No Data available this quarter, please select a different quarter.
23.86%
Similar OCF growth to CRVO's 24.16%. Walter Schloss would assume comparable operations or industry factors.
23.57%
FCF growth similar to CRVO's 24.16%. Walter Schloss would attribute it to parallel capital spending and operational models.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19211.55%
Negative 5Y OCF/share CAGR while CRVO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.46%
Negative 3Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15978.83%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-50766.69%
Negative 5Y net income/share CAGR while CRVO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
48.21%
3Y net income/share CAGR of 48.21% while CRVO is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
19776.75%
Equity/share CAGR of 19776.75% while CRVO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
4394.26%
Equity/share CAGR of 4394.26% while CRVO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
625.15%
Equity/share CAGR of 625.15% while CRVO is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Positive asset growth while CRVO is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
8.68%
Positive BV/share change while CRVO is negative. John Neff sees a clear edge over a competitor losing equity.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
108.24%
We expand SG&A while CRVO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.